SCHEMBL1660141

SCHEMBL1660141

Cc1ccc(S(=O)(=O)OCC[C@H](C)O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.43
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CA12 O43570 3/20 0.42
CA9 Q16790 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.41
GAA P10253 1/20 0.41
CYP2D6 P10635 2/20 0.40
CYP1A2 P05177 1/20 0.40
GBA1 P04062 1/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39
MMP13 P45452 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1120039 1.00 STAT3 (0.43) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL3979818 1.00 STAT3 (0.43) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL21239935 0.91 ALDH1A1 (0.41) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL1681609 0.91 ALDH1A1 (0.41) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL28641085 0.91 ALDH1A1 (0.43) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL5991018 0.90 PSMD10 (0.42) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL5569851 0.90 STAT3 (0.43) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL6936831 0.89 STAT3 (0.41) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL6936829 0.89 STAT3 (0.41) STAT3ALDH1A1MEN1KMT2ACA12
SCHEMBL7020906 0.89 PSMD10 (0.41) STAT3ALDH1A1MEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737443-A1 SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Tanabe Pharma Corporation (JP) 2026-05-06 EP disclosed
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2026-03-05 US disclosed
US-20240417388-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-12-19 US disclosed
US-12110286-B2 Benzimidazolone derived inhibitors of BCL6 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-08 US disclosed
US-20240199621-A1 MAP4K4 INHIBITORS IMPERIAL COLLEGE INNOVATIONS LTD (GB) 2024-06-20 US disclosed
EP-4374858-A2 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 Cancer Research Technology Limited (GB) 2024-05-29 EP disclosed
EP-3630291-B1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-01-10 EP disclosed
CN-112585147-B MAP4K4 inhibitors 帝国理工学院创新有限公司 2023-12-05 CN disclosed
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-0832061-B1 BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO (JP) 2001-09-05 EP disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed
US-6054457-A Benzamide derivatives and their use as vasopressin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-25 US disclosed
EP-0832061-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-04-01 EP disclosed
US-5641785-A ANTIDEPRESSANTS, NERVOUS SYSTEM DISORDERS SYNTHELABO (FR) 1997-06-24 US disclosed
WO-1996041795-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-12-27 WO disclosed
US-5196543-A Antidepressants, tranquilizers DELALANDE S.A. (FR) 1993-03-23 US disclosed
EP-0490407-A2 Process for the enzymatic separation of the optical isomers of tosyloxy-alkanols MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) 1992-06-17 EP disclosed
US-5036091-A Psychotropic drugs DELALANDE S.A. (FR) 1991-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME SIK1, SIK3, SIK2 STAT3 224/4885ALDH1A1 3731/4885MEN1 3747/4885
US-20240417388-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 BCL6, BCL6B, BCL3 STAT3 138/4885ALDH1A1 1654/4885MEN1 727/4885
US-11795169-B2 MAP4K4 inhibitors MAP4K4, MAP4K2, MAP4K5 STAT3 2701/4885ALDH1A1 1426/4885MEN1 1728/4885
US-20240199621-A1 MAP4K4 INHIBITORS MAP4K4, MAP4K2, MAP4K5 STAT3 2701/4885ALDH1A1 1426/4885MEN1 1728/4885
US-12110286-B2 Benzimidazolone derived inhibitors of BCL6 BCL6, BCL6B, BCL3 STAT3 138/4885ALDH1A1 1654/4885MEN1 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.